LG H&H Repositions The WHOO's Cheongidan as Science‑Driven Luxury with ...

LG H&H Repositions The WHOO’s Cheongidan as Science‑Driven Luxury with Third‑Generation Launch

LG Household & Health Care (LG H&H) has unveiled the third generation of Cheongidan, the flagship line of its luxury skincare brand The WHOO, signaling a strategic pivot from ingredient storytelling toward data‑driven, science‑based anti‑aging as it sharpens its focus on China and the global prestige beauty market.

The launch follows an unusually compressed renewal cycle. Cheongidan underwent its first major overhaul roughly 13 years after its debut, followed by a second upgrade just three years later, reflecting intensifying competition and rising scientific expectations in the premium skincare segment.

From a 13‑Year Gap to Accelerated Iteration

First introduced in January 2010, Cheongidan grew into one of Korea’s most successful luxury skincare franchises, surpassing ₩1 trillion (about $750 million) in annual sales as a single line by 2020.

In August 2023, LG H&H introduced what it now defines as second‑generation Cheongidan, unveiling the renewal at a large‑scale, art‑driven event in Shanghai. That iteration emphasized proprietary ingredients such as Cheonggibidan 12α and Gold Gardenia, positioning the line as a formula tailored to Asian skin tone and texture through heritage‑inspired ingredient innovation.

The third‑generation Cheongidan, launched globally in 2026, represents a far more fundamental reset.

From Ingredient Renewal to Human Genetics

Unlike the 2023 update, which centered on ingredient narratives, the latest Cheongidan is built on long‑term human data. LG H&H says the core formulation is based on an eight‑year genetic study involving more than 60,000 Asian participants, aimed at identifying skin characteristics unique to Asian populations.

Those findings were applied to develop: Chlorogen™, a radiance‑repair ingredient optimized for Asian skin biology, Niacinamide, re‑engineered within the formula for targeted brightening and tone correction.

The shift reflects what LG H&H describes as a “science‑driven luxury” approach—moving beyond symbolic ingredients toward measurable biological relevance.

Anti‑Aging Meets Brightening, Backed by Data

The third‑generation Cheongidan also introduces LG H&H’s proprietary Elastin Science technology, designed to reinforce skin structure by stimulating the production of eight types of collagen.

Company‑cited clinical testing showed: 79% improvement in cheek elasticity after four weeks of combined toner and emulsion use, 32% reduction in nasolabial and glabellar wrinkles, 572% improvement in skin radiance within one hour, 38% reduction in dark spots after four weeks

While earlier generations focused primarily on glow and elasticity, the latest Cheongidan is positioned explicitly as a “whitening anti‑aging” product, combining long‑term wrinkle care with short‑term visible brightening.

China at the Center of the Relaunch

LG H&H debuted the new Cheongidan on April 23, 2026, during Tmall’s Super Brand Day, China’s largest single‑brand e‑commerce event format. The company also staged an offline global launch in Shanghai, attended by The WHOO’s China and global ambassador, actor Li Xian, along with influencers and retail partners.

The dual online‑offline rollout underscores China’s central role in the brand’s strategy, at a time when domestic Chinese beauty brands (C‑beauty) are rapidly gaining share and international prestige labels face growing scrutiny over efficacy claims.

Industry observers view the move as part of a broader effort to redefine The WHOO’s luxury positioning—preserving its royal heritage identity while aligning with China’s rising demand for scientifically validated skincare.

The WHOO’s Cheongidan was revamped again about three years after its previous renewal in August 2023. (Image courtesy of LG Household & Health Care)

Why This Matters

Cheongidan’s evolution highlights a broader shift in the global luxury beauty market: heritage and storytelling alone are no longer sufficient. In China in particular, premium skincare brands are increasingly expected to demonstrate clinical proof, biological relevance, and quantifiable efficacy.

By accelerating its renewal cycle and anchoring its third‑generation launch in genetic research and human trials, LG H&H is signaling that K‑luxury skincare is entering a new phase—defined less by mythology and more by molecular credibility.

Whether the new Cheongidan can replicate—or exceed—its historic ₩1 trillion success remains to be seen. Strategically, however, the message is clear: The WHOO is no longer selling tradition alone, but validated science wrapped in luxury.